South Korea’s financial markets are bracing for sweeping regulatory changes as authorities move to tighten delisting rules, aiming to weed out so-called "zombie companies" but raising concerns about unintended casualties among financially stable firms. The Korea Exchange (KRX) announced on April 3, 2026, a significant revision to its listing regulations: starting in July, any stock trading below 1,000 won—commonly known as a "penny stock"—will be subject to delisting. This move, a direct follow-up to the government’s February 2026 reform plan for the swift and strict removal of insolvent companies, has ignited debate across the investment community and prompted a flurry of responses from industry stakeholders.
According to EBN, the KRX’s proposed changes reflect a broader push to improve the overall health of the capital markets. As of April 9, 2026, the exchange was actively soliciting feedback from market participants, with the consultation period set to close on April 10. The urgency behind this regulatory tightening is clear: the number of companies facing delisting for fiscal year 2025 remains high. The KRX revealed that a total of 54 listed firms—12 on the main KOSPI board and 42 on KOSDAQ—are at risk of being removed from the market due to reasons such as adverse audit opinions and severe capital erosion. While the headline numbers are similar to the previous year, the underlying message is that the authorities are not letting up in their efforts to force out underperforming or non-viable businesses.
But here’s where things get complicated. Critics warn that using stock price alone as a delisting trigger risks sweeping up companies that are, by most financial measures, healthy and even growing. Take CU Medical, for example—a specialist in automated external defibrillators (AEDs). Despite its shares trading below the 1,000 won threshold, CU Medical posted a 38% jump in operating profit in 2025, rising from 7.8 billion won to 10.8 billion won. This marked its third consecutive year of both sales and profit growth, and the company swung to a positive net income last year. Its price-to-book ratio (PBR) stands at 0.48, underlining that the market may be undervaluing the business. CU Medical’s interest coverage ratio is 3.9, far above the typical cutoff for so-called “zombie companies” (usually defined as firms with an interest coverage ratio below 1 for three straight years).
Other examples abound. Wavers, a developer of geographic information system (GIS) software, saw its operating profit climb 38% to 2 billion won in 2025. Saltware, a cloud infrastructure provider, turned profitable with an operating profit of 5.6 billion won. Both companies enjoy robust interest coverage ratios—34 and 4, respectively—indicating their ability to service debt is not in question. In the broadcasting sector, regional player TBC reported a 2% increase in operating profit last year and maintained a debt ratio of just 4.54%. That’s a world away from the KOSDAQ average of 113.10%, effectively making TBC a debt-free operator. Even KNN, another broadcaster that saw operating profit fall by 29%, kept its debt ratio at a stable 7.8%.
Despite these positive financial metrics, all these firms could be swept up in the new penny stock delisting net. This, say critics, could distort the market by unfairly labeling solid businesses as “zombie companies” and scaring off investors who might otherwise see value in these overlooked stocks. According to Maeil Business Newspaper, some companies have already started taking defensive measures. They are attempting stock consolidations or free capital reductions to boost their per-share price and dodge delisting. However, these tactics have their limits; if the post-consolidation price still falls below the new par value, the risk of delisting remains.
Industry voices are calling for a more nuanced approach. One representative from a KOSDAQ-listed firm told Maeil Business Newspaper, “Recently, capital has been flowing into IT and similar sectors, leaving other industries overlooked. There are plenty of penny stock companies with solid fundamentals, so rather than applying the delisting criteria across the board, we need targeted regulation that identifies truly marginal firms.”
Experts echo this sentiment, urging regulators to look beyond share price. Namwoo Lee, chairman of the Korea Corporate Governance Forum, emphasized, “When judging whether a company is a zombie, you have to look not just at the stock price but also whether its operating profit and cash flow are stable. The KOSDAQ market does have a lot of struggling companies, but financial statements need to be assessed qualitatively.”
Meanwhile, the delisting process itself is moving at a brisk pace. According to EBN, among the 54 companies facing delisting, 24 have been flagged for adverse audit opinions for two or more consecutive years—a key warning sign for investors. The KRX’s latest report highlights that all 12 KOSPI companies at risk were cited for adverse audit opinions, with seven receiving such opinions for the first time (including STX and Dynamic Design) and four, such as Kumyang and Sambutoken, receiving them for two years in a row. Hanchang, in a particularly dire spot, has been flagged for three consecutive years.
KOSDAQ paints a similar picture. Of the 42 firms facing delisting, 23 were new additions to the list, such as Daewonsys and Engchem Life Science. Eleven companies received adverse audit opinions for two straight years, while eight—including RF Semi and Terra Science—have been flagged for three years running. In addition, 43 companies have been newly designated as investment caution stocks, underscoring the heightened scrutiny in the current environment.
For companies notified of delisting risks, the process is strict but offers a narrow window for appeal. Firms have 15 business days from notification to file an objection, after which the KRX reviews the case and decides whether to grant a grace period. Those with persistent issues for two consecutive years face a final review by the listing or corporate review committees to determine whether they will be permanently removed from the market. Even companies that have addressed previous audit issues may still be subject to a final eligibility review.
All of this comes as the government and the KRX double down on their efforts to strengthen the market’s "immune system." The goal, as officials see it, is to ensure that only companies with genuine growth potential and sound management remain listed. Yet, the risk of collateral damage—where fundamentally healthy companies are swept up in a regulatory dragnet—remains a live concern.
Investors, especially individuals, are being urged to pay close attention. As one industry insider told EBN, “It’s not just about trading halts anymore. Actual delistings are happening, and they’re happening quickly. Investors need to be aware of these changes and focus on corporate value.”
The coming months will reveal whether the new rules strike the right balance between purging the market of dead weight and preserving opportunities for undervalued but fundamentally sound firms. For now, all eyes are on July—and on the companies scrambling to prove their worth before the ax falls.